← 返回

肝细胞癌中的预后基因及其功能:整合高通量空间转录组学与单细胞 RNA 测序的分析

英文原题:Prognostic genes in hepatocellular carcinoma and their function: an analysis integrating high-throughput-based spatial transcriptomics and single-cell RNA-sequencing.

查看英文原题

Prognostic genes in hepatocellular carcinoma and their function: an analysis integrating high-throughput-based spatial transcriptomics and single-cell RNA-sequencing.

PubMed 2026/03/25(内容时间) J Gastrointest Oncol Q3 · IF 2.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

识别肝细胞癌(HCC)患者的新型预后指标对改善结局至关重要,但绘制HCC肿瘤的空间组成仍具挑战。因此,本研究整合空间转录组测序(ST-seq)和单细胞RNA测序(scRNA-seq),旨在识别预后基因并评估其在HCC中的作用。

研究分析了包括癌症基因组图谱(TCGA)HCC、国际癌症基因组联盟(ICGC)HCC、GSE149614和GSE203612在内的HCC相关数据集。先进行单细胞和空间转录组分析,再开展细胞通讯分析,以识别比例存在差异且富集程度较高的目标细胞类型。采用最小绝对收缩和选择算子(LASSO)Cox回归筛选预后基因并构建风险模型。随后建立纳入独立预后因素的列线图,并分析免疫微环境和免疫治疗反应。最后通过拟时序分析确定目标细胞类型的发育轨迹。

在肝细胞、T/自然杀伤(NK)细胞、B细胞、髓系细胞、成纤维细胞和内皮细胞中,肝细胞与T/NK细胞被确定为目标细胞类型。空间转录组分析划分出7个细胞亚群(C0–C6)。细胞通讯分析显示,与T/NK细胞相比,肝细胞与其他细胞类型的相互作用更强。C4与其他细胞亚群之间的相互作用数量较多,但相互作用强度并非最高。7个预后基因中,ADH4、IGFBP3和LCAT在HCC中下调,AKR1B10、GAGE2A、MAGEA6和UCHL1上调。模型判定为高风险的患者生存期较短。由这7个预后基因构建的列线图能够较好地预测患者生存概率。在免疫浸润分析中,UCHL1表达与T/NK细胞丰度的正相关性最强。此外,计算机分析提示高风险状态可能与免疫治疗敏感性降低有关。拟时序分析显示,在肝细胞分化过程中,UCHL1、GAGE2A、MAGEA6、ADH4和LCAT的表达呈倒U形;在T/NK细胞分化末期,UCHL1表达升高。

本研究识别出HCC中的肝细胞、T/NK细胞及7个预后基因,构建了可预测患者预后的风险模型和列线图,并通过计算预测发现高风险组患者可能对免疫治疗反应较差,为HCC临床治疗提供了新的潜在工具。

展开英文摘要原文

Identifying novel prognostic indicators for patients with hepatocellular carcinoma (HCC) is critical to improving patient outcomes. Mapping the spatial composition of HCC tumors remains challenging. Therefore, this study aimed to identify prognostic genes and assess their role in HCC by integrating spatial transcriptome sequencing (ST-seq) and single-cell RNA sequencing (scRNA-seq).

HCC-related datasets, including The Cancer Genome Atlas (TCGA)-HCC, International Cancer Genome Consortium (ICGC)-HCC, GSE149614, and GSE203612, were examined in this study. Single-cell and spatial transcriptome analyses were first conducted and followed by cell communication analysis. Target cell types with differential proportions and higher enrichment were identified. Least absolute shrinkage and selection operator (LASSO) Cox regression analysis was implemented to select prognostic genes and construct a risk model. Subsequently, a nomogram incorporating independent prognostic factors was developed, and immune microenvironment and immunotherapy response were analyzed. Finally, pseudotime analysis was performed to determine the developmental trajectory of the target cell types.

Among hepatocytes, T/natural killer (NK) cells, B cells, myeloid cells, fibroblasts, and endothelial cells, hepatocytes and T/NK cells were identified as target cell types. ST analysis delineated seven cell subclusters (C0-C6). Cell communication analysis indicated that hepatocytes interact more strongly with other cell types compared to T/NK cells. The number of interactions between C4 and other cell subclusters was higher than the interaction intensity. Of the seven prognostic genes, ADH4 , IGFBP3 , and LCAT were downregulated in HCC, while AKR1B10 , GAGE2A , MAGEA6 , and UCHL1 were upregulated. The patients deemed to have a higher risk according to the model had shorter survival. The nomogram that was created by combining the seven prognostic genes had a good ability to forecast the patients' probability of survival. In the immunoinfiltration analysis, UCHL1 expression had the highest positive correlation with T/NK cell abundance. Moreover, in silico analysis suggested a potential association between high-risk status and reduced sensitivity to immunotherapy. Pseudotime analysis indicated that the expression of UCHL1 , GAGE2A , MAGEA6 , ADH4 , and LCAT displayed an inverted U shape during the differentiation of hepatocytes, with the expression of UCHL1 was elevated at the end of T/NK cell differentiation.

This study identified hepatocytes, T/NK cells, and seven prognostic genes in HCC, constructed a risk model and nomogram capable of predicting patient prognosis, and revealed through computational prediction that patients in the high-risk group might exhibit a poor response to immunotherapy, thereby providing new potential tools for the clinical treatment of HCC.

论文信息

作者
Zhang Y、Yao Y、Yan Z、He M、Tang Y、Zhang Z
第一作者单位
Department of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning, China.China
通讯作者单位
Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China.China
期刊
Journal of gastrointestinal oncology2026 Apr 30
原文标识
PubMed 42169880 · DOI 10.21037/jgo-2026-1-0014